You are here: Industry Insights > CTI BioPharma

News List

CTI BioPharma Announces Acceptance of NDA Granted with Priority Review of Pacritinib for Treatment of Patients with Myelofibrosis drugs
June 21, 2021
CTI BioPharma Corp.today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for pacritinib as a treatment for myelofibrosis patients with severe thrombocytopenia (platelet counts less than 50 x 109/L)
CTI BioPharma Announces Enrollment of First Patient in COVID-19 Trial americanpharmaceuticalreview
June 05, 2020
CTI BioPharma has enrolled the first patient in the Phase 3 PRE-VENT trial (NCT04404361) of pacritinib in hospitalized patients with severe COVID-19.
CTI Biopharma Announces Phase 3 Pacritinib for COVID-19 Hospitalized Patients americanpharmaceuticalreview
April 30, 2020
CTI BioPharma announced the initiation of PRE-VENT, a Phase 3 study evaluating pacritinib in hospitalized patients with severe COVID-19.
CTI BioPharma Initiates Phase III Pacritinib Trial in COVID-19 contractpharma
April 28, 2020
Will compare pacritinib plus standard of care versus placebo plus standard of care in 358 patients with severe COVID-19.
CTI BioPharma to Move to Phase 3 Study of Pacritinib for Myelofibrosis americanpharmaceuticalreview
July 19, 2019
CTI BioPharma announced the outcome of a Type B, End-of-Phase-2a meeting with the U.S. Food and Drug Administration (FDA) for the continued development of its investigational myelofibrosis treatment candidate, pacritinib. Following this meeting ...
CTI BioPharma Completes Enrollment of Phase 2 PAC203 Study of Pacritinib americanpharmaceuticalreview
December 29, 2018
CTI BioPharma announced the completion of full enrollment of 150 patients in the PAC203 Phase 2 study of pacritinib. The company expects to report the determination of ......
CTI, Servier’s Pixuvri fails in post-marketing trial pharmatimes
July 11, 2018
A late-stage trial of Servier and CTI BioPharma’s Pixuvri in combination with Roche's MabThera has failed to hit targets in B-cell non-Hodgkin lymphoma, putting its conditional approval in Europe in jeopardy.